Evidence map›Paper›PMID 28404844›Full record

ArticleJournal of virology2017

Intramuscular Immunization of Mice with the Live-Attenuated Herpes Simplex Virus 1 Vaccine Strain VC2 Expressing Equine Herpesvirus 1 (EHV-1) Glycoprotein D Generates Anti-EHV-1 Immune Responses in Mice.

Shiliang A Liu, Brent A Stanfield, Vladimir N Chouljenko, Shan Naidu, Ingeborg Langohr, Fabio Del Piero, Jacqueline Ferracone, Alma A Roy, Konstantin G Kousoulas

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. The Quest for Immunity: Exploring Human Herpesviruses as Vaccine Vectors.International journal of molecular sciences · 2023
    Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Shiliang A LiuDepartment of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, Louisiana, USA.
Brent A StanfieldDepartment of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, Louisiana, USA.
Vladimir N ChouljenkoDepartment of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, Louisiana, USA.
Shan NaiduDepartment of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, Louisiana, USA.
Ingeborg LangohrDepartment of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, Louisiana, USA.
Fabio Del PieroDepartment of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, Louisiana, USA.
Jacqueline FerraconeDepartment of Clinical Studies and Pathology, University of Pennsylvania School of Veterinary Medicine, Philadelphia, Pennsylvania, USA.
Alma A RoyDepartment of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, Louisiana, USA.
Konstantin G KousoulasDepartment of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, Louisiana, USA vtgusk@lsu.edu.
Louisiana State University · USUniversity of Pennsylvania · US

Funding

Telemedicine CoreP30GM110702 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI GARCIA-RILL, EDGAR E. · 2014 to 2018
$6.1M
NIGMS NIH HHS P30 GM110702
6 · The paper itself

Abstract

Vaccination remains the best option to combat equine herpesvirus 1 (EHV-1) infection, and several different strategies of vaccination have been investigated and developed over the past few decades. Herein, we report that the live-attenuated herpes simplex virus 1 (HSV-1) VC2 vaccine strain, which has been shown to be unable to enter into neurons and establish latency in mice, can be utilized as a vector for the heterologous expression of EHV-1 glycoprotein D (gD) and that the intramuscular immunization of mice results in strong antiviral humoral and cellular immune responses. The VC2-EHV-1-gD recombinant virus was constructed by inserting an EHV-1 gD expression cassette under the control of the cytomegalovirus immediate early promoter into the VC2 vector in place of the HSV-1 thymidine kinase (UL23) gene. The vaccines were introduced into mice through intramuscular injection. Vaccination with both the VC2-EHV-1-gD vaccine and the commercially available vaccine Vetera EHV

Indexed as

AnimalsAntibodies, NeutralizingAntibodies, ViralCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesDisease Models, AnimalHerpesviridae InfectionsHerpesvirus 1, EquidHerpesvirus VaccinesHorse DiseasesHorsesImmunity, CellularImmunity, HumoralImmunizationInjections, IntramuscularMiceAntibodies, NeutralizingAntibodies, Viralglycoprotein D, Equid herpesvirus 1Herpesvirus VaccinesVaccines, AttenuatedViral Envelope ProteinsViral VaccinesEHV-1equine herpesvirusglycoprotein DHSV-1immune responselive vector vaccinesmouse model

Identifiers

PMID28404844
PMCPMC5446645
OpenAlexW2605509544

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.